Key result
Mitral valve replacement in children and adolescents with severe rheumatic heart disease resulted in a 22% hospital mortality rate, with excellent functional improvement and no thromboembolic events among survivors.
Why the study?
Does mitral valve replacement improve outcomes in children and adolescents with severe rheumatic mitral incompetence refractory to medical treatment?
Observational (n=31)
No
Does mitral valve replacement improve outcomes in children and adolescents with severe rheumatic mitral incompetence refractory to medical treatment?
Mitral valve replacement provides beneficial results in children and adolescents with severe, medically refractory rheumatic mitral incompetence, despite a high operative mortality risk driven by poor baseline condition.
High mortality warrants caution for pediatric rheumatic MVR; leaves open optimal timing and selection in prospective studies.
To our knowledge, no documented hemodynamic studies in larger series of young patients undergoing valve replacement for rheumatic valvular disease have been reported previously. It seems to us that the natural history of rheumatic heart disease in India often follows a rapid and fulminant course which makes an aggressive surgical approach mandatory. An operative mortality of 22 % was seen in this series. Pronounced cardiac disability together with the poor general condition and the low nutritional status contributed in no small measure to this figure. Patients have been followed for periods ranging from 6 months to 6 years following corrective surgery. A remarkable absence of thrombo-embolic phenomena was a striking feature in the follow-up. There has been no evidence of rheumatic reactivation in any of these patients. This communication reinforces the beneficial results of valve replacement even at this young age when severe mitral incompetence exists refractory to medical treatment.
No takes yet. Share an insight, caveat, or question.
John et al. (1976) conducted an observational in Rheumatic Heart Disease (n=31). Mitral valve replacement was evaluated on Hospital mortality. Mitral valve replacement in children and adolescents with severe rheumatic heart disease resulted in a 22% hospital mortality rate, with excellent functional improvement and no thromboembolic events among survivors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: